Hantz Financial Services Inc. Has $3.22 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Hantz Financial Services Inc. increased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 3.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 226,685 shares of the company’s stock after acquiring an additional 6,967 shares during the quarter. Hantz Financial Services Inc.’s holdings in Takeda Pharmaceutical were worth $3,223,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its position in Takeda Pharmaceutical by 65.2% during the first quarter. Russell Investments Group Ltd. now owns 10,676 shares of the company’s stock worth $148,000 after acquiring an additional 4,213 shares during the last quarter. Cetera Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical during the first quarter worth $240,000. Simplicity Wealth LLC boosted its position in shares of Takeda Pharmaceutical by 4.0% in the second quarter. Simplicity Wealth LLC now owns 299,984 shares of the company’s stock valued at $3,882,000 after acquiring an additional 11,449 shares during the period. Manning & Napier Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the second quarter valued at about $4,098,000. Finally, OLD National Bancorp IN increased its position in Takeda Pharmaceutical by 7.9% during the second quarter. OLD National Bancorp IN now owns 31,261 shares of the company’s stock worth $405,000 after acquiring an additional 2,297 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $13.62 on Friday. The company has a market capitalization of $43.34 billion, a P/E ratio of 23.48, a P/E/G ratio of 0.25 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average price of $13.97 and a two-hundred day moving average price of $13.85.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.